Accelerating an ECS PIPELINE of Science-Backed Solutions
Our AI-powered pipeline of ECS-targeted innovations is focused on prescription therapeutics
This approach allows us to accelerate the development of novel, non-addictive compounds that target inflammatory, immune, and metabolic conditions—where conventional treatments often fall short.
Proofpoint: Endometriosis Therapeutics
A first-line, non-hormonal, disease modifying alternative for a major unmet need.
Endometriosis affects more than 200 million women worldwide, yet there is no cure. Current treatment options are limited, often hormone-based, and come with serious side effects—including infertility, bone density loss, mood disruption, and early menopause. Diagnosis takes an average of 7–10 years, pushing many women to self-manage symptoms: ~15% already use cannabinoids but want relief without the high.
This condition represents a $250B+ global market—and a major opportunity to introduce non-hormonal, first-line therapeutics for a population that is actively seeking safer, more effective options.
Key Differentiators
Nalu Bio’s ECS-targeted compounds are:
-
Engineered for precision modulation of specific GCPR receptors
-
Computer-assisted and AI-generated compounds solving for inflammatory, immune, and metabolic diseases
-
Patented novel chemical entities with enhanced bioavailability, stability, and selectivity over natural cannabinoids
-
As effective as NSAIDs and opioids, without the risk of addiction or intoxication.
Why It Matters
Women are already solving pain and stopping opioids with cannabinoids—95% report symptom improvement, and 66% have reduced or stopped opioid use entirely.
Women report symptom improvement
